FDA Panel Looks Beyond Xarelto’s Missing Data Problems To Broader Reforms
Executive Summary
Despite the agency’s decision to limit discussion about missing data to the ATLAS pivotal trial of rivaroxaban, Cardio-Renal advisory committee members suggested reforms that sponsors should consider to prevent the kinds of problems seen in ATLAS.